Conatus Pharmaceuticals Inc. buy tamam
Start price
24.09.15
/
50%
€59.64
Target price
24.03.16
€80.91
Performance (%)
-69.00%
End price
24.03.16
€18.49
Summary
This prediction ended on 24.03.16 with a price of €18.49. Massive losses of -69.00% were the result for the BUY prediction by tamam. tamam has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Conatus Pharmaceuticals Inc. | - | - | - | - |
iShares Core DAX® | 1.776% | 3.175% | 14.882% | 17.660% |
iShares Nasdaq 100 | -1.037% | 1.869% | 35.463% | 52.324% |
iShares Nikkei 225® | -0.335% | 3.857% | 14.485% | 11.459% |
iShares S&P 500 | 0.854% | 2.567% | 31.105% | 47.441% |
Comments by tamam for this prediction
In the thread Conatus Pharmaceuticals Inc. diskutieren
tamam stimmt dem eigenen Sentiment von 'Buy' zu
tamam stimmt am 24.09.2015 dem Buy-Crowdsentiment mit dem Kursziel 8.97$ zu.
Top-line results from a 23-subject Phase 2 clinical trial assessing Conatus Pharmaceuticals' (NASDAQ:CNAT) lead product candidate emricasan for the treatment of portal hypertension in patients with liver cirrhosis successfully demonstrated efficacy as determined by two outcome measures.
(Laufzeit überschritten)